vs
Side-by-side financial comparison of Crexendo, Inc. (CXDO) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $18.1M, roughly 1.0× Crexendo, Inc.). SCYNEXIS INC runs the higher net margin — 65.7% vs 6.7%, a 59.0% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 11.2%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 12.4%).
Crexendo, Inc. is a U.S.-headquartered cloud communications technology provider. It delivers unified communications as a service (UCaaS), contact center solutions, business VoIP services, and collaborative work tools, primarily catering to small and medium-sized enterprises operating in the North American market.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
CXDO vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.1M | $18.6M |
| Net Profit | $1.2M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 6.3% | 56.3% |
| Net Margin | 6.7% | 65.7% |
| Revenue YoY | 11.2% | 1808.5% |
| Net Profit YoY | 140.2% | 376.5% |
| EPS (diluted) | $0.03 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.1M | $18.6M | ||
| Q3 25 | $17.5M | $334.0K | ||
| Q2 25 | $16.6M | $1.4M | ||
| Q1 25 | $16.1M | $257.0K | ||
| Q4 24 | $16.2M | $977.0K | ||
| Q3 24 | $15.6M | $660.0K | ||
| Q2 24 | $14.7M | $736.0K | ||
| Q1 24 | $14.3M | $1.4M |
| Q4 25 | $1.2M | $12.3M | ||
| Q3 25 | $1.4M | $-8.6M | ||
| Q2 25 | $1.2M | $-6.9M | ||
| Q1 25 | $1.2M | $-5.4M | ||
| Q4 24 | $507.0K | — | ||
| Q3 24 | $148.0K | $-2.8M | ||
| Q2 24 | $588.0K | $-14.5M | ||
| Q1 24 | $434.0K | $411.0K |
| Q4 25 | 6.3% | 56.3% | ||
| Q3 25 | 7.5% | -2516.5% | ||
| Q2 25 | 6.7% | -701.0% | ||
| Q1 25 | 7.2% | -3350.2% | ||
| Q4 24 | 3.9% | — | ||
| Q3 24 | 0.9% | -1563.6% | ||
| Q2 24 | 3.9% | -1255.0% | ||
| Q1 24 | 3.4% | -692.5% |
| Q4 25 | 6.7% | 65.7% | ||
| Q3 25 | 8.3% | -2572.2% | ||
| Q2 25 | 7.4% | -504.8% | ||
| Q1 25 | 7.3% | -2097.7% | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 0.9% | -425.5% | ||
| Q2 24 | 4.0% | -1964.4% | ||
| Q1 24 | 3.0% | 29.9% |
| Q4 25 | $0.03 | $0.25 | ||
| Q3 25 | $0.05 | $-0.17 | ||
| Q2 25 | $0.04 | $-0.14 | ||
| Q1 25 | $0.04 | $-0.11 | ||
| Q4 24 | $0.03 | — | ||
| Q3 24 | $0.00 | $-0.06 | ||
| Q2 24 | $0.02 | $-0.30 | ||
| Q1 24 | $0.01 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | $114.0K | — |
| Stockholders' EquityBook value | $63.8M | $49.4M |
| Total Assets | $77.7M | $59.0M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | $114.0K | — | ||
| Q3 25 | $236.0K | — | ||
| Q2 25 | $356.0K | — | ||
| Q1 25 | $475.0K | — | ||
| Q4 24 | $592.0K | — | ||
| Q3 24 | $709.0K | — | ||
| Q2 24 | $823.0K | — | ||
| Q1 24 | $937.0K | — |
| Q4 25 | $63.8M | $49.4M | ||
| Q3 25 | $61.3M | $36.4M | ||
| Q2 25 | $58.3M | $44.5M | ||
| Q1 25 | $55.2M | $50.5M | ||
| Q4 24 | $51.4M | $55.1M | ||
| Q3 24 | $49.5M | $58.5M | ||
| Q2 24 | $48.2M | $60.4M | ||
| Q1 24 | $46.8M | $74.1M |
| Q4 25 | $77.7M | $59.0M | ||
| Q3 25 | $76.0M | $51.1M | ||
| Q2 25 | $71.4M | $60.7M | ||
| Q1 25 | $67.4M | $67.9M | ||
| Q4 24 | $64.9M | $90.6M | ||
| Q3 24 | $62.3M | $99.0M | ||
| Q2 24 | $59.6M | $107.8M | ||
| Q1 24 | $57.5M | $118.3M |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.3M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.93× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3M | $18.4M | ||
| Q3 25 | $4.4M | $-8.7M | ||
| Q2 25 | $1.3M | $-7.5M | ||
| Q1 25 | $1.2M | $-7.5M | ||
| Q4 24 | $2.2M | $-24.0M | ||
| Q3 24 | $1.6M | $765.0K | ||
| Q2 24 | $2.7M | $-10.9M | ||
| Q1 24 | $-166.0K | $-4.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $1.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 1.93× | 1.50× | ||
| Q3 25 | 3.05× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 4.29× | — | ||
| Q3 24 | 10.95× | — | ||
| Q2 24 | 4.51× | — | ||
| Q1 24 | -0.38× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CXDO
| Services | $8.6M | 48% |
| Software Solution Segment | $8.3M | 46% |
| Products | $1.1M | 6% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
